[New oral anticoagulants - influence on coagulation tests].
Journal article

[New oral anticoagulants - influence on coagulation tests].

  • Simeon L Abteilung für Hämatologie und Hämatologisches Zentrallabor, Luzerner Kantonsspital, Schweiz.
  • Nagler M Universitätsklinik für Hämatologie und Hämatologisches Zentrallabor, Inselspital, Bern, Schweiz.
  • Wuillemin WA Abteilung für Hämatologie und Hämatologisches Zentrallabor, Luzerner Kantonsspital, Schweiz.
  • 2014-01-09
Published in:
  • Deutsche medizinische Wochenschrift (1946). - 2014
English The new oral anticoagulants (NOACs) represent alternative antithrombotic agents for prophylaxis and therapy of thromboembolic diseases. They act either by inhibition of the clotting factor Xa or IIa (thrombin). As a consequence, they influence several coagulation assays (for example prothrombin time, activated partial thromboplastin time). Because of the short half-life of these new agents, these changes show great variations in the course of 24 hours. Furthermore, there are significant differences of laboratory results depending on the used reagents. We explain the influence of apixaban, rivaroxaban (factor Xa inhibitors) and dabigatran (thrombin inhibitor) on the most commonly used coagulation assays. Besides we show that this influence depends on the way of action of the drug as well as on the principle of the coagulation assay. Being aware of this relationships helps to interpret the results of coagulation assays under influence of NOACs correctly.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://sonar.ch/global/documents/235596
Statistics

Document views: 10 File downloads: